BPIQ Blog

Summary: Phase 2b ETNB ENLIVEN data was reported today (3/22/23) & trial met primary endpoints How does this data compare to previous...

Summary: ITCI, NRXP & VTGN are left in our March Movers list, all are in the mental health category NRXP & VTGN are March Big Movers and...

Summary: The IONS and BIIB AdComm meeting for Tofersen is scheduled for this Wednesday, March 22! Briefing docs were released today...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

We're coming down to the final weeks of Q1 2023. This past week XBI finished green up ~1%, although it still sits in the mid $70's. See...

Summary: The CDTX PDUFA for Rezafungin to treat candidemia and invasive candidiasis is scheduled for March 22 Positive Phase 3 data from...

Summary: The American Association for Cancer Research (AACR) 2023 Annual Meeting will take place from April 14-19, 2023, abstracts...

Each week we're posting a countdown of the remaining catalysts left in Q1! Last week was a rough week for biotech's with XBI finishing...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: The ACAD Trofinetide PDUFA is expected this Sunday March 12, 2023 Will we see an early decision before the weekend? See our full...

First published 3/6/23 - currently in progress Summary: ESPR CLEAR outcomes data from NEXLETOL trial reported over the weekend at ACC.23...

Last week was a green week for XBI (biotech ETF), which finished the week up +2.3%, see the biggest news from last week, including a full...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: Several recent oncology investor conferences are still available to the public, including all company webcasts These conferences...

First posted 3/10/2023; last updated 5/1/2023 Summary: Many exciting rare diseases catalysts are coming throughout the year See the table...

Last week was a tough week for biotech, XBI (biotech ETF) saw a 6% pullback, see the biggest news from last week, including a full table...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: Reata Pharmaceuticals has a PDUFA data for Omaveloxolone for FA 2/28/23. The previous PDUFA date was extended 3 months after...

Summary: The upcoming readout from ETNB includes Phase 2b data from the pegozafermin trial in NASH. This is a Suspected Mover for Q1...

Last updated 4/11/23 Summary: Many exciting blood cancer & disease catalysts are coming throughout the year See the table below for some...